Lexicon Pharmaceuticals Inc. (LXRX) Financial Statements (2025 and earlier)

Company Profile

Business Address 2445 TECHNOLOGY FOREST BLVD.
THE WOODLANDS, TX 77381
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments170,026138,35786,743152,275271,659160,052
Cash and cash equivalents22,46546,34564,065126,26336,11280,386
Short-term investments147,56192,01222,67826,012235,54779,666
Receivables1,010281439556,5325,924
Inventory, net of allowances, customer advances and progress billings381   4,2434,680
Inventory381   4,2434,680
Other current assets5,1302,4812,1645,0495,3202,668
Total current assets:176,547140,86688,921157,719337,754173,324
Noncurrent Assets
Operating lease, right-of-use asset5,524    
Property, plant and equipment1,9872,0711,17629514,04715,865
Intangible assets, net (including goodwill)44,54344,54344,54344,54364,25994,662
Goodwill44,54344,54344,54344,54344,54344,543
Intangible assets, net (excluding goodwill)     19,71650,119
Other noncurrent assets8286,8192,2691,2311,655285
Total noncurrent assets:52,88253,43347,98846,06979,961110,812
TOTAL ASSETS:229,429194,299136,909203,788417,715284,136
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31,54623,17222,12435,16054,32932,241
Accounts payable14,38910,3959,1525,46912,17817,759
Accrued liabilities17,15712,77712,97229,69142,15114,482
Debt    11,64611,0121,115
Other undisclosed current liabilities      3,395
Total current liabilities:31,54623,17222,12446,80665,34136,751
Noncurrent Liabilities
Long-term debt and lease obligation, including:99,5085,424  1,102243,887
Long-term debt, excluding current maturities99,508   234,171243,887
Other undisclosed long-term debt and lease obligation  5,424  (233,069) 
Liabilities, other than long-term debt5,2655,4241,1906111,1026,252
Deferred tax liabilities, net6,014
Other liabilities 5,4241,1906111,102238
Operating lease, liability 5,265    
Other undisclosed noncurrent liabilities  43,155  233,06923,651
Total noncurrent liabilities:104,77354,0031,190611235,273273,790
Total liabilities:136,31977,17523,31447,417300,614310,541
Equity
Equity, attributable to parent93,110117,124113,595156,371117,101(26,405)
Common stock245189150142106106
Treasury stock, value(2,885)(2,061)(7,518)(4,843)(3,817)(2,876)
Additional paid in capital1,862,5581,709,1441,608,7491,561,0961,462,1721,447,954
Accumulated other comprehensive income (loss)31(428)(10)(6)84(12)
Accumulated deficit(1,766,839)(1,589,720)(1,487,776)(1,400,018)(1,341,444)(1,471,577)
Total equity:93,110117,124113,595156,371117,101(26,405)
TOTAL LIABILITIES AND EQUITY:229,429194,299136,909203,788417,715284,136

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues1,20413929823,995322,07363,209
Cost of revenue
(Cost of Goods and Services Sold)
(85)  (1,929)(3,231)(2,491)
Gross profit:1,11913929822,066318,84260,718
Operating expenses(172,869)(100,899)(87,388)(204,380)(180,628)(166,488)
Other undisclosed operating income    134,5143,2312,491
Operating income (loss):(171,750)(100,760)(87,090)(47,800)141,445(103,279)
Nonoperating income
(Other Nonoperating income)
7,7321,5961342,7673,3503,508
Interest and debt expense  (2,780)(802)(13,541)(20,676)(20,777)
Other undisclosed income from continuing operations before equity method investments, income taxes      
Income (loss) from continuing operations before income taxes:(164,018)(101,944)(87,758)(58,574)124,119(120,548)
Income tax benefit    2695,569 
Income (loss) from continuing operations:(164,018)(101,944)(87,758)(58,305)129,688(120,548)
Income (loss) before gain (loss) on sale of properties:(87,758)(70,505)129,688(120,548)
Loss from discontinued operations    (12,200)  
Other undisclosed net income    11,931445 
Net income (loss):(164,018)(101,944)(87,758)(58,574)130,133(120,548)
Other undisclosed net loss attributable to parent(13,101)     
Net income (loss) available to common stockholders, basic:(177,119)(101,944)(87,758)(58,574)130,133(120,548)
Dilutive securities, effect on basic earnings per share   (87,758)(58,574)135,200 
Net income (loss) available to common stockholders, diluted:(177,119)(101,944)(175,516)(117,148)265,333(120,548)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(164,018)(101,944)(87,758)(58,574)130,133(120,548)
Comprehensive income (loss):(164,018)(101,944)(87,758)(58,574)130,133(120,548)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(12,642)(418)(4)(90)96210
Comprehensive income (loss), net of tax, attributable to parent:(176,660)(102,362)(87,762)(58,664)130,229(120,338)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: